NVCR News and Press, NovoCure Limited From 01/19/23

Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17. Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new executive role as Chief Growth Officer. In this role, Mr. Shah will have worldwide responsibilit...

Novocure (NASDAQ: NVCR) announced good news earlier this month from a late-stage study evaluating its Tumor-Treating Fields (TTFields) therapy in treating non-small cell lung cancer (NSCLC). Its shares skyrocketed. But just a few days later, the company provided a sneak peek at its ...

H.C. Wainwright reaffirmed the Buy rating on oncology-focused medical equipment maker NovoCure Limited ( NASDAQ: NVCR ) on Thursday despite a loss of ~16% of its value early this week after pre-announcing lower-than-expected Q4 financials. The maker of the Optune brand of cancer treat...

Novocure ( NASDAQ: NVCR ) is down ~15% in Monday afternoon trading after releasing preliminary Q4 2022 figures that came in below estimates. The oncology focused pharma is expecting Q4 net revenue of $128.4 million, below the consensus in $128.69M. As of December 31, 2022, the...

Summary Powered by the robust Phase 3 (LUNAR) trial, NovoCure Limited shares recently rallied over 70% in one trading session. You can expect Tumor Treating Field to be approved for non-small cell lung cancer sometime next year. Later this year, two huge Phase 3 studies are set to r...

Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival Novocure announces first patients t...

Shares of NovoCure (NASDAQ: NVCR) , a maker of niche medical devices, shot about 68% higher on Jan. 5. Investors were cheering clinical trial results for what could be the company's most important product to date. Is NovoCure a good stock to buy now, or will its recent gains fizzl...

Novocure (NASDAQ: NVCR) stock rallied hard during Thursday's trading session while most growth stocks were selling off. In the video below, I explain why the stock is flying high. I also share a brief background of Novocure and look at a chart to tell you where the stock could be headed nex...

Shares of Chinese biotech company Zai Lab Limited (NASDAQ: ZLAB) were up more than 59.2% for the week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence . The stock closed at $30.70 on Friday and rose to as high as $49.81 on Thursday. Zai La...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CHIARI VFX / Shutterstock Huadi International (NASDAQ: HUDI ) stock is climbing higher on Thursday even without specific news from the Chinese steel company. What appears to be behind today’s moveme...